AAPL346.98+3.07 (+0.89%) ▲|ABBV286.55-0.20 (-0.07%) ▼|ABT103.13-1.75 (-1.67%) ▼|ACN235.11-12.12 (-4.90%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.98-2.07 (-0.66%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B543.07-5.49 (-1.00%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.32-3.69 (-1.59%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.09-0.88 (-0.38%) ▼|DIS110.24-0.16 (-0.14%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.22+0.00 (+0.00%) ▲|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|AAPL346.98+3.07 (+0.89%) ▲|ABBV286.55-0.20 (-0.07%) ▼|ABT103.13-1.75 (-1.67%) ▼|ACN235.11-12.12 (-4.90%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.98-2.07 (-0.66%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B543.07-5.49 (-1.00%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.32-3.69 (-1.59%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.09-0.88 (-0.38%) ▼|DIS110.24-0.16 (-0.14%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.22+0.00 (+0.00%) ▲|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|
16.8 C
New York
Tuesday, October 27, 2026

Tag: trials

newsFORsourcecompanycontentinformation1releasesmarket

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as...

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain.Following successful Phase I results...

Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation

Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring evidence-driven...

Aspivix Joins the Afaxys GPO to Expand Access to carevix® Across the U.S. Public Health Community

The new agreement gives Afaxys members access to carevix®, an FDA-cleared cervical stabilizer, clinically proven to reduce pain and bleeding during IUD insertion procedures.LOS...

Vitaceuticals Launches MagZorb Joint Ease with NEM Nationwide

Australians crack 6.87 billion eggs a year. Joint health research says we're throwing away the best bit.SYDNEY, Oct. 20, 2026 /PRNewswire/ -- The paper-thin...

Fabarta Unveils Major Upgrade to Its AI4S Platform: RSI Engine Connects Materials Discovery, Digital Pilot-Scale Trials and Industrial Mass Production

Powered by the upgraded RSI engine, the platform unifies data, models, experiments and production to accelerate materials innovationBEIJING, Oct. 19, 2026 /PRNewswire/ -- Fabarta...

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective...

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

STOCKHOLM, Oct. 19, 2026 /PRNewswire/ -- Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society...

Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative...

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label...

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

Scalare Launches EquityRoom, Adding a Subscription Revenue Stream to Its Founder Ecosystem

HighlightsEquityRoom, Scalare's startup fundraising, data room and equity management platform, launched on 6 October 2026.11 paying customers at launch, with a further 35 customers...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers